Influenza ›

There is an estimated average of 200,000 hospitalizations and up to 36,000 deaths from the flu every year in the US. In addition to the tremendous loss of life, the global impact on economic productivity is enormous. Recent estimates put the total economic burden of seasonal influenza epidemics at approximately US $87.1 billion every year in the United States alone. As a consequence, the World Health Organization recommends that anyone considered at high risk should be vaccinated.

US Product Information

Fluvirin influenza virus vaccine
(purified surface antigen vaccine)

Fluvirin Influenza Virus Vaccine (Surface Antigen) is a sterile parenteral for intramuscular use only. It is a purified split-virus preparation.
The vaccine is a slightly opalescent liquid.

Download the full product information

 

AGRIFLU® Influenza Virus Vaccine

AGRIFLU® is an inactivated vaccine indicated for active immunization for the prevention of disease caused by influenza virus subtypes A and type B contained in the vaccine. AGRIFLU is approved for use in persons 18 years of age and older.

Download the full product information

Japanese Encephalitis ›

Japanese encephalitis is a viral infection that was first observed in Japan in 1870. Japanese encephalitis is a mosquito-borne disease caused by a flavivirus and transmitted throughout Asia.

With Approximately 50,000 cases and 15,000 deaths reported each year, Japanese encephalitis is the most frequent and most severe viral encephalitis, and the leading cause of viral neurological infection among children in Asia.

US Product Information

Ixiaro® was developed to provide a well-tolerated, effective and convenient vaccine against JE, suitable for administration to travelers who wish to reduce their risk of acquiring the disease. A vaccine against Japanese Encephalitis has been available for travelers from the US, however its use has been limited by concerns over its safety profile and a recent announcement of discontinued production. Ixiaro has been shown to be as immunogenic as the currently licensed JE vaccine but with a better local tolerability profile and a more convenient dosing schedule.

About Ixiaro Vaccine
Ixiaro is indicated for active immunization against JE virus for persons 17 years of age and older. Ixiaro is a purified inactivated state-of-the-art JE vaccine that uses cell culture technology. It provides a good immune response while being well tolerated. It does not contain thiomersal, gelatin or any other stabilizers or preservatives in its formulation. The vaccine is provided as a ready-to-use liquid formulation in pre-filled syringes and is administered in two doses 28 days apart.

Download the full product information

Rabies ›

Rabies is a fatal infectious disease caused when the rabies virus invades the central nervous system. Rabies is most often spread from animal to animal or animal to human through contact with infected saliva via a bite or scratch. Approximately 60,000 rabies deaths are reported globally every year and up to 50 % of all rabies victims are children.

US Product Information

Rabavert

Novartis's purified chick embryo cell rabies vaccine (trademarked as RabAvert) is the most widely used high quality cell culture vaccine with more than 55 million doses administered in ~70 countries worldwide.
RabAvert is WHO recommended and FDA approved. A proven pre-exposure vaccination and post-exposure prophylaxis for all age groups.

Download the full product information
(129 KB)

Influenza A(H1N1) 2009 monovalent vaccine ›

 

Novartis Influenza A(H1N1) 2009 monovalent vaccine was approved by the FDA on September 15, 2009. The A(H1N1) vaccine is an inactivated subunit vaccine approved for active immunization of persons 4 years of age and older, including patients with underlying chronic medical conditions. The US Department of Health and Human Services (HHS) awarded Novartis two contracts totaling USD 979 million for purchase of H1N1 bulk vaccine and the Novartis proprietary MF59 adjuvant.

Download full product information